A matrix metalloproteinase inhibitor, ONO-4817, retards the development of mammary tumor and the progression of uterine adenomyosis in mice.

Takao Mori, Mori T, Keiko Nakahashi, Nakahashi K, Kyokuwa M, Miho Kyokuwa, Shinichi Yamasaki, Yamasaki S, Shin‐ichi Yamasaki, Nagasawa H, Hiroshi Nagasawa
Anticancer research · 2003 · vol. 22(6C) , pp. 3985–8 · PMID:12553022 · W2415181981
article OA: closed CC0 ⤵ 7 in-corpus citations
View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06, 2026-06-13 ⓘ

The matrix metalloproteinase inhibitor ONO-4817 extended the tumor-free periods of mice with spontaneous mammary tumors and reduced the pathological progression of experimentally induced uterine adenomyosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The inhibitory effects of a novel matrix metalloproteinase inhibitor, ONO-4817, on the development of mammary tumors and the progression of uterine adenomyosis were examined in SHN mice. First, multiparous mice which developed mammary tumors spontaneously were used. The first palpable tumor was removed, and the mice were thereafter fed chow containing ONO-4817. Any second mammary tumor developing in the other mammary fat pad was also removed, and the mice were continuously fed the chow containing ONO-4817. The mice were killed when a third tumor was detected in the other fat pad. The periods between the occurrence of the first and second tumors, and the second and third ones were significantly increased in the mice treated with ONO-4817 compared to the mice not given ONO-4817 treatment. Second, to test ONO-4817 suppression of the progression of the invasion of uterine adenomyotic tissue, mice with experimentally-induced adenomyosis were treated with ONO-4817 for 4 weeks. The degree of pathological progression of adenomyosis was less in the uteri exposed to ONO-4817 than in the uteri not exposed to the inhibitor.

My notes (saved in your browser only)

Condition tags

endometriosisadenomyosis

MeSH descriptors

Anticarcinogenic Agents Endometriosis Enzyme Inhibitors Mammary Neoplasms, Experimental Phenyl Ethers Uterine Diseases Animals Anticarcinogenic Agents Endometriosis Endometriosis Endometrium Endometrium Endometrium Enzyme Inhibitors Female Mammary Neoplasms, Experimental Matrix Metalloproteinase Inhibitors Mice Phenyl Ethers Uterine Diseases

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

Cited by (7)

Source provenance

europepmc
last seen: 2026-07-27T06:15:28.040536+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:12:55.732728+00:00
License: CC0 · commercial use OK